



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Celgosivir

Item No. 36526

CAS Registry No.: 121104-96-9
Formal Name: butanoic acid, (1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indolizinyloxy ester
Synonyms: 6-O-butanoyl Castanospermine, MDL 28574
MF: C₁₂H₂₁NO₅
FW: 259.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Celgosivir is supplied as a solid. A stock solution may be made by dissolving the celgosivir in the solvent of choice, which should be purged with an inert gas. Celgosivir is slightly soluble in chloroform and DMSO.

Description

Celgosivir is an α -glucosidase inhibitor ($IC_{50} = 0.7 \mu\text{g/ml}$) and a prodrug form of the α - and β -glucosidase inhibitor castanospermine (Item No. 11313).^{1,2} It reduces bovine viral diarrhea virus (BVDV) levels in a plaque formation assay ($IC_{50} = 16 \text{ mM}$) and increases the survival of bovine kidney (MDBK) cells infected with BVDV ($IC_{50} = 47 \mu\text{M}$).³ Intraperitoneal administration of celgosivir (50 mg/kg twice daily) reduces viremia and increases the survival of mice infected with a lethal dose of dengue virus.⁴

References

1. Sunkara, P.S., Kang, M.S., Bowlin, T.L., *et al.* Inhibition of glycoprotein processing and HIV replication by castanospermine analogues. *Ann. NY Acad. Sci.* **616**, 90-96 (1990).
2. Winchester, B.G., di Bello, I.C., Richardson, A.C., *et al.* The structural basis of the inhibition of human glycosidases by castanospermine analogues. *Biochem. J.* **269(1)**, 227-231 (1990).
3. Whitby, K., Taylor, D., Patel, D., *et al.* Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: Implications for the treatment of hepatitis C. *Antivir. Chem. Chemother.* **15(3)**, 141-151 (2004).
4. Watanabe, S., Rathore, A.P.S., Sung, C., *et al.* Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. *Antiviral Res.* **96(1)**, 32-35 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/02/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM